The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer

Lujun Zhao, Kerby Sheldon, Ming Chen, Moli S. Yin, James A. Hayman, Gregory P. Kalemkerian, Doug Arenberg, Susan E. Lyons, Jeffrey L. Curtis, Mary Davis, Kemp B. Cease, Dean Brenner, Mitchell S. Anscher, Theodore S. Lawrence, Feng Ming Kong

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Background: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study.

Original languageEnglish (US)
Pages (from-to)232-239
Number of pages8
JournalLung Cancer
Volume59
Issue number2
DOIs
StatePublished - Feb 1 2008

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Radiation
Lung
Radiation Pneumonitis
Blood Platelets
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity

Keywords

  • Lung cancer
  • Radiation therapy
  • Radiation-induced lung toxicity
  • Transforming growth factor β1

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. / Zhao, Lujun; Sheldon, Kerby; Chen, Ming; Yin, Moli S.; Hayman, James A.; Kalemkerian, Gregory P.; Arenberg, Doug; Lyons, Susan E.; Curtis, Jeffrey L.; Davis, Mary; Cease, Kemp B.; Brenner, Dean; Anscher, Mitchell S.; Lawrence, Theodore S.; Kong, Feng Ming.

In: Lung Cancer, Vol. 59, No. 2, 01.02.2008, p. 232-239.

Research output: Contribution to journalArticle

Zhao, L, Sheldon, K, Chen, M, Yin, MS, Hayman, JA, Kalemkerian, GP, Arenberg, D, Lyons, SE, Curtis, JL, Davis, M, Cease, KB, Brenner, D, Anscher, MS, Lawrence, TS & Kong, FM 2008, 'The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer', Lung Cancer, vol. 59, no. 2, pp. 232-239. https://doi.org/10.1016/j.lungcan.2007.08.010
Zhao, Lujun ; Sheldon, Kerby ; Chen, Ming ; Yin, Moli S. ; Hayman, James A. ; Kalemkerian, Gregory P. ; Arenberg, Doug ; Lyons, Susan E. ; Curtis, Jeffrey L. ; Davis, Mary ; Cease, Kemp B. ; Brenner, Dean ; Anscher, Mitchell S. ; Lawrence, Theodore S. ; Kong, Feng Ming. / The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer. In: Lung Cancer. 2008 ; Vol. 59, No. 2. pp. 232-239.
@article{61f06718848f465e8555ea631bd8bb1b,
title = "The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer",
abstract = "Background: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1{\%}) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7{\%} and 95.0{\%}, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study.",
keywords = "Lung cancer, Radiation therapy, Radiation-induced lung toxicity, Transforming growth factor β1",
author = "Lujun Zhao and Kerby Sheldon and Ming Chen and Yin, {Moli S.} and Hayman, {James A.} and Kalemkerian, {Gregory P.} and Doug Arenberg and Lyons, {Susan E.} and Curtis, {Jeffrey L.} and Mary Davis and Cease, {Kemp B.} and Dean Brenner and Anscher, {Mitchell S.} and Lawrence, {Theodore S.} and Kong, {Feng Ming}",
year = "2008",
month = "2",
day = "1",
doi = "10.1016/j.lungcan.2007.08.010",
language = "English (US)",
volume = "59",
pages = "232--239",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - The predictive role of plasma TGF-β1 during radiation therapy for radiation-induced lung toxicity deserves further study in patients with non-small cell lung cancer

AU - Zhao, Lujun

AU - Sheldon, Kerby

AU - Chen, Ming

AU - Yin, Moli S.

AU - Hayman, James A.

AU - Kalemkerian, Gregory P.

AU - Arenberg, Doug

AU - Lyons, Susan E.

AU - Curtis, Jeffrey L.

AU - Davis, Mary

AU - Cease, Kemp B.

AU - Brenner, Dean

AU - Anscher, Mitchell S.

AU - Lawrence, Theodore S.

AU - Kong, Feng Ming

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Background: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study.

AB - Background: This study aimed to further investigate the role of circulating TGF-β1 during radiation therapy (RT) in predicting radiation-induced lung toxicity (RILT). Methods and materials: Patients with stages I-III non-small cell lung cancer treated with RT based therapy were included in this study. Platelet poor plasma was obtained pre-RT, at 2 and 4 weeks during-RT, and at the end of RT. TGF-β1 was measured using an enzyme-linked immunosorbent assay. The primary endpoint for RILT was ≥grade 2 radiation pneumonitis or fibrosis. Results: Twenty-six patients with a minimum follow-up of 12 months were included. Six patients (23.1%) experienced ≥grade 2 RILT. There was no significant difference in absolute TGF-β1 levels pre-RT, at 2 and 4 weeks during-RT, or at the end of RT between patients with and without RILT. The TGF-β1 ratios (over the pre-RT levels) for patients with and without RILT at 2, 4 weeks during-, and the end of RT were 2.8 ± 2.2 and 1.0 ± 0.6 (P = 0.123), 2.3 ± 1.3 and 0.8 ± 0.5 (P = 0.001), 1.5 ± 0.9 and 0.8 ± 0.5 (P = 0.098), respectively. Using 2.0 as a cut-off, the TGF-β1 ratio at 4 weeks during-RT predicted RILT with a sensitivity and specificity of 66.7% and 95.0%, respectively. Conclusion: Elevation of plasma TGF-β1 level 4 weeks during-RT is significantly predictive of RILT. The role of plasma TGF-β1 in predicting RILT deserves further study.

KW - Lung cancer

KW - Radiation therapy

KW - Radiation-induced lung toxicity

KW - Transforming growth factor β1

UR - http://www.scopus.com/inward/record.url?scp=38649099697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38649099697&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2007.08.010

DO - 10.1016/j.lungcan.2007.08.010

M3 - Article

C2 - 17905467

AN - SCOPUS:38649099697

VL - 59

SP - 232

EP - 239

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -